Please amend the claims as presented below:

- 1. (Original) A DNA vaccine composition comprising a recombinant construct comprising an isolated nucleic acid sequence encoding an antigen selected from CD25, homologs and fragments thereof; the nucleic acid sequence being operably linked to one or more transcription control sequences; and a pharmaceutically acceptable carrier, adjuvant, excipient or diluent.
- 2. (Original) The composition of claim 1, wherein the CD25 is human CD25.
- 3. (Original) The composition of claim 1, wherein the isolated nucleic acid sequence has a nucleic acid sequence as set forth in SEQ ID NO:1.
- 4. (Original) The composition of claim 1, wherein the isolated nucleic acid sequence encodes an antigen having an amino acid sequence as set forth in any one of SEQ ID NOS:2-4.
- 5. (Original) The composition of claim 1, wherein the composition is a naked DNA vaccine.
- 6. (Original) The composition of claim 1, wherein said carrier is selected from the group consisting of liposomes, micelles, emulsions and cells.
- 7. (Original) The composition of claim 1, wherein said transcription control sequences are selected from the group consisting of: RSV control sequences, CMV control sequences, retroviral LTR sequences, SV-40 control sequences and β-actin control sequences.
- 8. (Original) The composition of claim 1, wherein said recombinant construct is a eukaryotic expression vector.
- 9. (Original) The composition of claim 8, wherein said eukaryotic expression vector is selected from the group consisting of: pcDNA3, pcDNA3.1(+/-), pZeoSV2(+/-), pSecTag2, pDisplay, pEF/myc/cyto, pCMV/myc/cyto, pCR3.1, pCI, pBK-RSV, pBK-CMV and pTRES.
- 10. (Original) A method of preventing or inhibiting the development of a T-cell mediated pathology, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising: (a) a recombinant construct, said recombinant construct comprising an isolated nucleic acid sequence encoding an antigen selected from: CD25, homologs and fragments thereof, wherein the nucleic acid sequence is operably

linked to one or more transcription control sequences; and (b) a pharmaceutically acceptable carrier, excipient or diluent.

- 11. (Original) The method of claim 10, wherein the CD25 is human CD25.
- 12. (Original) The method of claim 10, wherein the isolated nucleic acid sequence is as set forth in SEQ ID NO:1.
- 13. (Original) The method of claim 10, wherein the isolated nucleic acid sequence encodes an antigen having an amino acid sequence as set forth in any one of SEQ ID NOS:2-4.
- 14. (Original) The method of claim 10, wherein said T cell-mediated pathology is an autoimmune disease.
- 15. (Original) The method of claim 14, wherein said T cell-mediated autoimmune disease is selected from the group consisting of: multiple sclerosis, rheumatoid arthritis, autoimmune neuritis, systemic lupus erythematosus, psoriasis, Type I diabetes mellitus, Sjogren's disease, thyroid disease and myasthenia gravis.
- 16. (Original) The method of claim 10, wherein said T cell-mediated pathology is graft rejection.
- 17. (Original) The method of claim 10, wherein said T cell-mediated pathology is a Th1-mediated inflammatory disease.
- 18. (Original) The method of claim 10, wherein the antigen is expressed in sufficient amount and duration to increase anti-ergotypic T cell response in said subject, thereby inhibiting or preventing the development of said T-cell mediated pathology.
- 19. (Original) The method of claim 18, wherein said increase in anti-ergotypic T cell response is characterized by a reduction in the secretion of IFNy and an increase in the secretion of IL-10.
- 20. (Original) The method of claim 10, wherein the nucleic acid composition is administered as naked DNA.
- 21. (Original) The method of claim 10, wherein said subject is human.
- 22. (Original) A method for preventing or inhibiting the development of a T-cell mediated pathology comprising the steps of (a) obtaining cells from a subject; (b) transfecting

the cells *in vitro* with a recombinant construct comprising an isolated nucleic acid sequence encoding an antigen selected from: CD25, homologs and fragments thereof, the nucleic acid sequence being operably linked to one or more transcription control sequences; and (c) reintroducing a therapeutically effective number of the transfected cells to the subject, thereby preventing or inhibiting the development of the T-cell mediated pathology.

- 23. (Original) The method of claim 22, wherein the CD25 is human CD25.
- 24. (Original) The method of claim 22, wherein the isolated nucleic acid sequence is as set forth in SEQ ID NO:1.
- 25. (Original) The method of claim 22, wherein the isolated nucleic acid sequence encodes an antigen having an amino acid sequence as set forth in any one of SEQ ID NOS:2-4.
- 26. (Original) The method of claim 22, wherein said T cell-mediated pathology is an autoimmune disease.
- 27. (Original) The method of claim 26, wherein said T cell-mediated autoimmune disease is selected from the group consisting of: multiple sclerosis, rheumatoid arthritis, autoimmune neuritis, systemic lupus erythematosus, psoriasis, Type I diabetes mellitus, Sjogren's disease, thyroid disease and myasthenia gravis.
- 28. (Original) The method of claim 22, wherein said T cell-mediated pathology is graft rejection.
- 29. (Original) The method of claim 22, wherein said T cell-mediated pathology is a Th1-mediated inflammatory disease.
- 30. (Original) The method of claim 22, wherein the antigen is expressed in sufficient amount and duration to increase anti-ergotypic T cell response in said subject, thereby inhibiting or preventing the development of said T-cell mediated pathology.
- 31. (Original) The method of claim 30, wherein said increase in anti-ergotypic T cell response is characterized by a reduction in the secretion of IFNy and an increase in the secretion of IL-10.
- 32. (Original) The method of claim 22, wherein said subject is human.
- 33-48 Cancelled.